Nuera Pharmaceuticals Private Limited
About Nuera Pharmaceuticals Private Limited
Data last updated:
Nuera Pharmaceuticals Private Limited is a private limited company based in Bhopal, Madhya Pradesh, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 11 September 2014 and has been in existence for over 12 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U24232MP2014PTC033179. Its GSTIN is 23AAECN7444C1ZR (Madhya Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Himanshu Joshi and Prashant Gujar.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at H.No. 12 Behind D Mart, Bhopal, Madhya Pradesh, India – 462008.
As per the financials filed for FY 2025, the company reported a revenue of ₹31.23 Lakh, a growth of 73% compared to the previous year. For the same year it recorded a net loss of ₹10,354 (net margin -0.3%) and EBITDA of -₹1,160 (EBITDA margin 0%). Revenue has grown at a compounded annual rate (CAGR) of 87% over three years and 8% over five years.
As per MCA filings, the company has open charges of ₹10.1 Lakh on record.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Nuera Pharmaceuticals Private Limited's registered office is in Bhopal, Madhya Pradesh. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressH.No. 12 Behind D Mart, Bhopal, Madhya Pradesh, India – 462008
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of Nuera Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Nuera Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Nuera Pharmaceuticals Private Limited, buy the company report.
Financials of Nuera Pharmaceuticals Private Limited
FY 2025 filings availableNuera Pharmaceuticals Private Limited reported revenue of ₹31.23 Lakh (up 73% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 73% growth in the latest year. EBITDA fell 127% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹1,160 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹10,354 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 0% | ||||
| Net Profit Margin | -0.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Nuera Pharmaceuticals Private Limited, buy the company report.
Board of directors of Nuera Pharmaceuticals Private Limited
Nuera Pharmaceuticals has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Himanshu Joshi | Director | 10 Jun 2023 | 3 Years 4 Months | Current |
| Prashant Gujar | Director | 10 Jun 2023 | 3 Years 4 Months | Current |
Peer comparison
Nuera Pharmaceuticals Private Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Styron Pharmaceuticals Private Limited | ₹31.32 Lakh (FY 2025) | 52.0% | Agra, Uttar Pradesh, India | |||
| Nuera Pharmaceuticals Private Limitedthis company | ₹31.23 Lakh (FY 2025) | -₹10,354 | -0.3% | 73.0% | Bhopal, Madhya Pradesh, India | |
| Vidakem Lifesciences Private Limited | ₹31.18 Lakh (FY 2025) | -100.0% | Ahmedabad, Gujarat, India | |||
| Biotical Pharmaceuticals Private Limited | ₹31.18 Lakh (FY 2025) | -54.0% | Ahmedabad, Gujarat, India | |||
| Nigella Pharmaceuticals Private Limited | ₹31.17 Lakh (FY 2025) | 61.0% | Haridwar, Uttarakhand, India |
To see the full peer comparison of Nuera Pharmaceuticals Private Limited, buy the company report.
Auditor
Nuera Pharmaceuticals Private Limited is audited by SANJEEV OMPRAKASH GARG & CO for the financial year 2020.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| SANJEEV OMPRAKASH GARG & CO | FY 2020 | 008773C |
Shareholding
The shareholding of Nuera Pharmaceuticals Private Limited is on record for 3 financial years, the latest being FY 2020, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2020 | FY 2017 | FY 2016 |
|---|---|---|---|
| Promoters | |||
| Domestic institutional investors (DII) | |||
| Foreign institutional investors (FII) | |||
| Public | |||
| Others |
To see the full shareholding pattern of Nuera Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 20 Sep 2025 | 101162804 | State Bank of India | ₹10.1 Lakh | Open |
Total charge records: 1 View all charges
Legal cases
No court or tribunal cases involving Nuera Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Nuera Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Nuera Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AAECN7444C1ZR | Madhya Pradesh | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Nuera Pharmaceuticals Private Limited, buy the company report.
Recent activity
Nuera Pharmaceuticals Private Limited has 9 board changes on record since 2015: 2 appointments and 7 cessations. The latest: Jogeshwar Tiwari ceased to be Director on 18 Nov 2024.
1 earlier event is in the company report.
Frequently asked questions
Nuera Pharmaceuticals is an active private limited company based in Bhopal, Madhya Pradesh, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 11 September 2014 (12+ years old) and is registered under CIN U24232MP2014PTC033179.
Nuera Pharmaceuticals has 2 current directors:
- Himanshu Joshi - Director
- Prashant Gujar - Director
The latest financial statements of Nuera Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Nuera Pharmaceuticals is 23AAECN7444C1ZR, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Nuera Pharmaceuticals is U24232MP2014PTC033179. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nuera Pharmaceuticals was incorporated on 11 September 2014, making it 12+ years old. It is registered with the Registrar of Companies, Gwalior.
The peers of Nuera Pharmaceuticals by revenue are Styron Pharmaceuticals Private Limited, Vidakem Lifesciences Private Limited, Biotical Pharmaceuticals Private Limited, Nigella Pharmaceuticals Private Limited, all in the Pharma industry (Pharma Retail and Distribution, Pharmaceuticals), with the same principal business activity (wholesale trading).
Jogeshwar Tiwari ceased to be Director on 18 Nov 2024. Himanshu Joshi ceased to be Additional Director on 29 Sep 2023. Prashant Gujar ceased to be Additional Director on 29 Sep 2023. Nuera Pharmaceuticals has 9 board changes on record in total.
The registered office of Nuera Pharmaceuticals is at H.No. 12 Behind D Mart, Bhopal, Madhya Pradesh, India – 462008.
Nuera Pharmaceuticals operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
Nuera Pharmaceuticals has open charges of ₹10.1 Lakh and no satisfied charges on record as per latest MCA filings.